Continuous positive airway pressure for central sleep apnea and heart failure.

BACKGROUND The Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure trial tested the hypothesis that continuous positive airway pressure (CPAP) would improve the survival rate without heart transplantation of patients who have central sleep apnea and heart failure. METHODS After medical therapy was optimized, 258 patients who had heart failure (mean age [+/-SD], 63+/-10 years; ejection fraction, 24.5+/-7.7 percent) and central sleep apnea (number of episodes of apnea and hypopnea per hour of sleep, 40+/-16) were randomly assigned to receive CPAP (128 patients) or no CPAP (130 patients) and were followed for a mean of two years. During follow-up, sleep studies were conducted and measurements of the ejection fraction, exercise capacity, quality of life, and neurohormones were obtained. RESULTS Three months after undergoing randomization, the CPAP group, as compared with the control group, had greater reductions in the frequency of episodes of apnea and hypopnea (-21+/-16 vs. -2+/-18 per hour, P<0.001) and in norepinephrine levels (-1.03+/-1.84 vs. 0.02+/-0.99 nmol per liter, P=0.009), and greater increases in the mean nocturnal oxygen saturation (1.6+/-2.8 percent vs. 0.4+/-2.5 percent, P<0.001), ejection fraction (2.2+/-5.4 percent vs. 0.4+/-5.3 percent, P=0.02), and the distance walked in six minutes (20.0+/-55 vs. -0.8+/-64.8 m, P=0.016). There were no differences between the control group and the CPAP group in the number of hospitalizations, quality of life, or atrial natriuretic peptide levels. An early divergence in survival rates without heart transplantation favored the control group, but after 18 months the divergence favored the CPAP group, yet the overall event rates (death and heart transplantation) did not differ (32 vs. 32 events, respectively; P=0.54). CONCLUSIONS Although CPAP attenuated central sleep apnea, improved nocturnal oxygenation, increased the ejection fraction, lowered norepinephrine levels, and increased the distance walked in six minutes, it did not affect survival. Our data do not support the use of CPAP to extend life in patients who have central sleep apnea and heart failure.

[1]  Daniel J Buysse,et al.  Sleep–Related Breathing Disorders in Adults: Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research , 2000 .

[2]  T. Douglas Bradley,et al.  Sleep Apnea and Heart Failure: Part I: Obstructive Sleep Apnea , 2003, Circulation.

[3]  A. Logan,et al.  Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. , 2000, Circulation.

[4]  M. Esler,et al.  Acute Effects of Continuous Positive Airway Pressure on Cardiac Sympathetic Tone in Congestive Heart Failure , 2001, Circulation.

[5]  J S Floras,et al.  Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. , 1999, American journal of respiratory and critical care medicine.

[6]  M. Kryger,et al.  The effect of short-term nasal CPAP on Cheyne-Stokes respiration in congestive heart failure. , 1992, Chest.

[7]  M. Naughton,et al.  Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. , 1995, American journal of respiratory and critical care medicine.

[8]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[9]  A. Xie,et al.  Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure , 1991, The Lancet.

[10]  Thomas Penzel,et al.  Effect of Nasal Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients With Obstructive Sleep Apnea , 2003, Circulation.

[11]  J. McMurray,et al.  Fortnightly Review: Diagnosis and management of heart failure , 1994, BMJ.

[12]  S. O’Keeffe,et al.  Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients , 1998, Heart.

[13]  D. Schoenfeld,et al.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.

[14]  A. Logan,et al.  Rationale and design of the Canadian Continuous Positive Airway Pressure Trial for Congestive Heart Failure patients with Central Sleep Apnea--CANPAP. , 2001, The Canadian journal of cardiology.

[15]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[16]  J. Stradling,et al.  Nasal continuous positive airway pressure in chronic heart failure with sleep-disordered breathing. , 1993, The American review of respiratory disease.

[17]  J. Floras,et al.  Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. , 1995, Circulation.

[18]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[19]  T. Bradley,et al.  Sleep apnea and cardiovascular disease. , 2001, American journal of respiratory and critical care medicine.

[20]  M. Naughton,et al.  Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. , 1997, Journal of the American College of Cardiology.

[21]  P. Hanly,et al.  Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. , 1996, American journal of respiratory and critical care medicine.

[22]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in heart failure , 1989, Journal of General Internal Medicine.

[23]  R. Goldstein,et al.  Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure. , 1995, American journal of respiratory and critical care medicine.

[24]  Jose M Marin,et al.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study , 2005, The Lancet.

[25]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[26]  K. Chin,et al.  Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. , 1996, American journal of respiratory and critical care medicine.

[27]  C. Guilleminault,et al.  EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. , 1992, Sleep.

[28]  C. Guilleminault,et al.  Cardiac failure and benzodiazepines. , 1993, Sleep.

[29]  J. Dempsey,et al.  Assessment of inspiratory flow limitation invasively and noninvasively during sleep. , 1998, American journal of respiratory and critical care medicine.

[30]  C. Lyketsos,et al.  Antipsychotic drugs in dementia: what should be made of the risks? , 2005, JAMA.

[31]  T Douglas Bradley,et al.  Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. , 2003, The New England journal of medicine.

[32]  A. Rechtschaffen.  A manual of standardized terminology, techniques and scoring system for sleep of human subjects , 1968 .

[33]  P. McLaughlin,et al.  Cardiac output response to continuous positive airway pressure in congestive heart failure. , 1992, The American review of respiratory disease.

[34]  G. Bernardi,et al.  Cerebral hemodynamic changes in sleep apnea syndrome and effect of continuous positive airway pressure treatment , 1998, Neurology.

[35]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[36]  B A Staats,et al.  Chest wall motion in sleep apnea. , 1984, The American review of respiratory disease.

[37]  J. Floras,et al.  Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. , 2005, Journal of the American College of Cardiology.

[38]  A. Rechtschaffen,et al.  A manual of standardized terminology, technique and scoring system for sleep stages of human subjects , 1968 .

[39]  R. Lefkowitz,et al.  Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. , 2004, The Journal of clinical investigation.

[40]  J. Brophy,et al.  Diagnosis and management of heart failure. Canadian Cardiovascular Society. , 1994, The Canadian journal of cardiology.

[41]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[42]  K. Franklin,et al.  Sleep apnoea and nocturnal angina , 1995, The Lancet.

[43]  R Colombo,et al.  Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. , 1999, Circulation.

[44]  S. Javaheri,et al.  Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. , 1998, Circulation.

[45]  M. Naughton,et al.  Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. , 2004, American journal of respiratory and critical care medicine.

[46]  T Douglas Bradley,et al.  Sleep Apnea and Heart Failure: Part II: Central Sleep Apnea , 2003, Circulation.

[47]  Michael Miller,et al.  Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. , 1995, Chest.